Belinostat is under clinical development by Acrotech Biopharma and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase I drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Belinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Belinostat overview
Belinostat (Beleodaq) is a antineoplastic drug, belongs to oncology class. It is formulated as a lyophilized powder for solution for intravenous route of administration. Beleodaq is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma.
It is under development for the treatment of unresectable and metastatic conventional chondrosarcoma, metastatic triple-negative breast cancer, ovarian cancer, urothelial carcinoma, gastrointestinal malignancies including gastric cancer, colorectal cancer, metastatic castration resistant prostate cancer, pancreatic cancer, metastatic uveal melanoma and gynecological malignancies including metastatic ovarian cancer and endometrial cancer, relapsed refractory acute myeloid leukemia and myelodysplastic syndrome, metastatic breast cancer, thymoma( thymic epithelial tumor), refractory solid tumors, hematological malignancies (i.v), liquid and solid tumors (oral). It is administered through intravenous and oral routes. It was under development as second-line therapy for peripheral T-cell lymphoma, fallopian tube cancer, peritoneal cancer, epithelial ovarian cancer and also under development for acute myelocytic leukemia, B-cell lymphomas, advanced multiple myeloma, small-cell lung cancer, epithelial carcinoma, soft tissue sarcoma, thymic carcinoma (second line), hepatocellular carcinoma, diffuse large b-cell lymphoma (third line), angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma, follicular T cell lymphoma, extra-nodal natural killer cell lymphoma and non-small lung cancer (first-line therapy). The oral formulation of belinostat is developed based on amorphous spray-dried dispersion technology.
It was also under development for the treatment of thymic carcinoma.
Acrotech Biopharma overview
Acrotech Biopharma (Acrotech), a subsidiary of Aurobindo Pharma USA Inc develops and commercializes innovative proprietary medications. The company provides products in the therapy areas of gastrointestinal, oncology and genetic disorders.
For a complete picture of Belinostat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
